trending Market Intelligence /marketintelligence/en/news-insights/trending/KrI-3YdEJycjrduirvQ4lQ2 content esgSubNav
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us
In This List

Calif. regulator investigating Merck & Co. unit for potential insurance fraud

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Calif. regulator investigating Merck & Co. unit for potential insurance fraud

Merck & Co. Inc. said it received a subpoena from the California Insurance Commissioner's Fraud Liaison Bureau seeking information related to the pricing and promotion of its antibiotic drug Cubicin.

The bureau is investigating whether Merck's Cubist Pharmaceuticals Inc. made false insurance claims for Cubicin.

Merck acquired Cubist in 2015, gaining access to Cubicin, which is used to treat bacterial infections.

Further, the company revealed that a French appeals court ruled in June that Merck & Co. indulged in trademark infringement or unfair competition against Germany's Merck KGaA through certain activities in France.

Merck KGaA had sued the company in France, the U.K., Germany, Switzerland, Mexico and India, alleging breach of the parties' co-existence agreement as well as trademark infringement.

Under a 1955 co-existence agreement, later revised in 1970, Merck & Co. is required to brand itself as MSD outside U.S. and Canada, while Merck KGaA is required to identify itself as EMD in the two markets.